Sprycel
E1584915
UNEXPLORED
Sprycel is a prescription cancer medication (dasatinib) used primarily to treat certain types of leukemia, including chronic myeloid leukemia (CML) and Philadelphia chromosome–positive acute lymphoblastic leukemia (Ph+ ALL).
All labels observed (2)
How this entity was disambiguated
This entity first appeared as the object of triple T23417458 — resolving that mention is where its identity was fixed. The disambiguator weighed these candidate entities and picked the highlighted one (or “None”, minting a new entity). This is how homonymy is resolved: the same surface form can point to different entities.
NED1
Entity disambiguation (via context triple)
gpt-5-mini-2025-08-07
Target entity: Sprycel Context triple: [Bristol Myers Squibb, product, Sprycel]
-
A.
Gleevec
Gleevec is a groundbreaking targeted cancer therapy, best known for treating chronic myeloid leukemia by inhibiting the BCR-ABL tyrosine kinase.
-
B.
Tasigna
Tasigna is a prescription tyrosine kinase inhibitor used primarily to treat certain types of Philadelphia chromosome–positive chronic myeloid leukemia (CML) in adults and children.
-
C.
Iclusig
Iclusig is a cancer medication containing ponatinib, primarily used to treat certain types of leukemia such as chronic myeloid leukemia (CML) and Philadelphia chromosome–positive acute lymphoblastic leukemia (Ph+ ALL).
-
D.
Venclexta
Venclexta is a targeted cancer therapy (venetoclax) used primarily to treat certain types of leukemia by inhibiting the BCL-2 protein that helps cancer cells survive.
-
E.
Imbruvica
Imbruvica is a targeted cancer therapy (a Bruton's tyrosine kinase inhibitor) used primarily to treat certain types of blood cancers such as mantle cell lymphoma and chronic lymphocytic leukemia.
- F. None of above. chosen
- G. Unsure - the case is ambiguous/there is not enough information to decide.
NED2
Entity disambiguation (via description)
gpt-5-mini-2025-08-07
Target entity: Sprycel Target entity description: Sprycel is a prescription cancer medication (dasatinib) used primarily to treat certain types of leukemia, including chronic myeloid leukemia (CML) and Philadelphia chromosome–positive acute lymphoblastic leukemia (Ph+ ALL).
-
A.
Gleevec
Gleevec is a groundbreaking targeted cancer therapy, best known for treating chronic myeloid leukemia by inhibiting the BCR-ABL tyrosine kinase.
-
B.
Tasigna
Tasigna is a prescription tyrosine kinase inhibitor used primarily to treat certain types of Philadelphia chromosome–positive chronic myeloid leukemia (CML) in adults and children.
-
C.
Iclusig
Iclusig is a cancer medication containing ponatinib, primarily used to treat certain types of leukemia such as chronic myeloid leukemia (CML) and Philadelphia chromosome–positive acute lymphoblastic leukemia (Ph+ ALL).
-
D.
Venclexta
Venclexta is a targeted cancer therapy (venetoclax) used primarily to treat certain types of leukemia by inhibiting the BCL-2 protein that helps cancer cells survive.
-
E.
Imbruvica
Imbruvica is a targeted cancer therapy (a Bruton's tyrosine kinase inhibitor) used primarily to treat certain types of blood cancers such as mantle cell lymphoma and chronic lymphocytic leukemia.
- F. None of above. chosen
Referenced by (2)
Full triples — surface form annotated when it differs from this entity's canonical label.
linked to: Sprycel